Drug intelligence / Profile preview

RGD-SLN

Development stage: Preclinical
Lead developer: Ontario Cancer Institute
Modality: Nanoparticles → Drug Delivery Systems, Peptides
Administration: Intravenous

Overview

RGD-SLN (RGD-conjugated solid lipid nanoparticles) is a preclinical-stage targeted nanoparticle formulation developed for the treatment of integrin αvβ3-overexpressing cancers, particularly metastatic breast cancer. The formulation consists of a fatty acid lipid core and a poly(ethylene glycol) (PEG) corona decorated with cyclic Arg-Gly-Asp (cRGD) peptides. By targeting the αvβ3 integrin receptor, RGD-SLN is designed to inhibit tumor cell adhesion, migration, and invasion, thereby preventing metastasis. The formulation has been optimized to maximize tumor accumulation and retention while minimizing liver uptake.

Other names: RGD-conjugated solid lipid nanoparticlescRGD-SLNcyclic RGD-conjugated solid lipid nanoparticles

Targets

αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)

Beyond the preview

Go deeper on RGD-SLN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGD-SLN.

Explore the full profile